An observational study in Hepatocellular Carcinoma, sponsored by GlaxoSmithKline. Completed at 1 site in Italy. Per ClinicalTrials.gov, last updated 2009-12-24.
Sponsored by GlaxoSmithKline · Observational
Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these. As a first step in the development of novel therapies, expression analysis of specific markers, including tumor antigens will be carried out. This will be done retrospectively using available hepatocellular carcinoma tissue samples.
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's enrollment of 30 is below the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Primary care clinic
Exclusion Criteria:
N/A
No intervention
Other: Retrospective analysis of already archived samples
RNA extracted from tissue samples already archived
This study will also analyze whether this gene-expression signature is present in matched cirrhotic tissue and the interface tissue with the tumor.
Time frame: At the time of analysis.
Proportion of hepatocellular carcinoma cancer patients whose tumor tissue -expresses any one or more of specific target antigens -overexpresses c-MET -expresses a pre-defied gene-expression signature
Time frame: At the time of analysis.
This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline